AstraZeneca Adds Cancer Drugs to Pipeline with Innate Pharma Deal
October 23 2018 - 10:31AM
Dow Jones News
By Denise Roland
LONDON-- AstraZeneca PLC has struck a deal with a French
biotechnology firm to add a promising cancer drug to its pipeline,
boosting its focus on oncology as part of broader strategy to
double sales in the next five years.
AstraZeneca said it would take full ownership of a drug called
monalizumab, which has shown potential in treating head and neck
cancer in clinical trials, as part of an expanded collaboration
pact with Innate Pharma SA.
AstraZeneca will also gain access to a second cancer drug in
Innate's pipeline, dubbed IPH5201, and the right to license four
to-be-agreed medicines in early-stage development at the French
company.
It will pay Innate $170 million upfront and potentially more in
the future depending on the success of the drugs. AstraZeneca will
also take a 9.8% stake in Innate Pharma.
AstraZeneca has pivoted toward cancer drug development in recent
years as part of its ambition to boost annual revenue to $40
billion by 2023. The company generated $22.5 billion in sales last
year.
The Innate deal will bolster a key plank of AstraZeneca's cancer
pipeline: drugs, known as immunotherapies, that enhance the body's
immune response to tumor cells.
Such drugs are attracting heavy investment from several big
drugmakers and have had success with some hard-to-treat cancers. In
addition to head and neck cancer, AstraZeneca is testing
monalizumab in colorectal cancer, for which there are currently no
available immunotherapies. It also plans to test the drug in other
tumor types.
The deal builds on AstraZeneca Chief Executive Pascal Soriot's
strategy of seeking better treatment results through combining
cancer drugs.
AstraZeneca has had mixed fortunes on this front. Its
combination treatment for lung cancer failed a key clinical trial
last year, although the company is awaiting follow-up data that
could overturn that result.
"The future is made of combinations," Mr. Soriot said in an
interview Tuesday. "The problem is to unlock the right
combination."
AstraZeneca is already testing monalizumab in combination with
another immunotherapy drug. Dr. Soriot said he planned on testing
IPH5201 in combination with another drug in early development at
the Cambridge, England-based company.
As part of the deal, Innate will pay $50 million for the right
to sell Lumoxiti, a drug developed by AstraZeneca to treat a rare
form of cancer known as hairy-cell leukemia, in the U.S. and
Europe. Innate will pay AstraZeneca a further $25 million if the
drug hits particular regulatory and commercial milestones.
Dr. Soriot said the agreement on Lumoxti would secure the drug's
long-term commercial future.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
October 23, 2018 10:16 ET (14:16 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Innate Pharma (EU:IPH)
Historical Stock Chart
From Jul 2023 to Jul 2024